Article Text

PDF

The effect of topical glaucoma medications evaluated by perimetry
  1. J-C Lin1,
  2. F Samuel1,
  3. L J Katz1,
  4. G L Spaeth1,
  5. J Hoop2,
  6. L B Cantor2
  1. 1William and Anna Goldberg Glaucoma Service, Wills Eye Hospital, and the Department of Ophthalmology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA
  2. 2Indiana University School of Medicine, Department of Ophthalmology, Indianapolis, IN, USA
  1. Correspondence to: L Jay Katz, MD, Glaucoma Service, Wills Eye Hospital, 840 Walnut Street, Suite 1110, Philadelphia, PA 19107, USA; LJK22222{at}aol.com

Statistics from Altmetric.com

The emphasis of treatment for glaucoma has been the reduction of intraocular pressure (IOP) to a safer level, which, in turn, theoretically will prevent further visual loss. It has been assumed that lowering IOP by medical means has no adverse effect, which could negate the beneficial effect of IOP reduction. However, several reports have raised the possibility that some may adversely affect visual function.1,2 In several studies betaxolol and timolol were compared with respect to their effect on IOP reduction and perimetric findings.3–5 Although timolol lowered IOP more effectively, betaxolol was more effective in preserving the visual field.

These findings suggest that IOP reduction is not the only parameter that demands attention. In this study, we attempted to evaluate various topical antiglaucoma medications in a normal population in terms of their short term effect on visual function; only minimal effects on IOP reduction were expected since this study population did not have glaucoma.

Methods

Five prospective, randomised, masked studies of levobunolol, dipivefrin, apraclonidine, betaxolol, and dorzolamide, respectively, were conducted over 5 years. In each study, 20 normal volunteers had baseline testing, including measurement of visual acuity (VA), IOP, visual field (VF) with the Humphrey computerised perimeter (HCP) program 24-2, and pupil size. One eye was randomly assigned to treatment and given a test dose of either a glaucoma medication or a placebo. VF testing was repeated in 1 hour. The same eye was later given the opposite drop (the drug if a placebo was used, a placebo if the drug was used) and a third set of visual field studies was done. Paired t test and signed rank test were used in the statistical analysis.

All subjects had normal ocular examinations, with best corrected visual acuity of 20/30 or better. The mean baseline IOP was 13.3 mm Hg right eye and 13.5 mm Hg left eye (range 10–18 mm Hg). When levobunolol was administered, there was a mean deviation of −2.9 dB compared with −1.9 dB for the placebo (p<0.05) (Table 1). There were no significant differences in terms of other global values (short term fluctuation, pattern standard deviation, and corrected pattern standard deviation), visual acuity, and pupil size.

Table 1

Effects of topical glaucoma medications on automated perimetry

Thus, in a normal population, a single dose of several topical glaucoma medications had little or no effect on perimetry. The possible mild suppression of retinal sensitivity with levobunolol is of unknown clinical significance.

Comment

Flammer and Drance tested several drugs topically, all of which reduced retinal sensitivity on threshold perimetry in contrast with oral acetazolamide, which improved perimetry results in 75 patients with elevated IOP or in the very early stages of chronic open angle glaucoma.6 Paterson found that acute IOP reduction increased retinal sensitivity.7 Martin-Boglind and coworkers showed that the influence of topical glaucoma medications (epinephrine, timolol, betaxolol, pilocarpine) on the high pass resolution threshold was negligible in normal subjects.8 Edgar and coworkers found no significant change with dipivefrin in normal subjects.9 In our studies, only levobunolol caused a mild generalised decrease in visual function compared to controls on visual field testing of normal subjects. Short term fluctuation was not altered and there was no relative focal defect when levobunolol was compared with placebo. Since these were controlled trials, the placebo effect was not a factor. Vasoactivity, direct effect on neuronal elements, corneal epithelial alteration, and refractive change of current glaucoma drugs should be also considered. The mechanism by which various topical glaucoma medications affect retinal sensitivity remains unclear. The effect may be due to changes in blood flow to the posterior segment of eye. Further study is needed.

References

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.